Hepatocellular carcinoma
Conditions
Interventions
all patients :Transarterial infusion of bevacizumab
all patients :Routine-TACE
Sponsors
The first teaching hospital of Xinjiang medical university
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. TACE-refractory hepatocellular carcinoma; 2. ChildPugh A/B/C, no encephalopathy and ascites and pleural effusion need treatment; 3. ECOG performance status of 0-2; 4. Measurable tumors; 5. 18 years of age or older; 6. Life expectancy of > 12 weeks; 7. Adequate hepatic and renal function: ALB>=28g/L, TBIL=50*10^9/L.
Exclusion criteria
Exclusion criteria: 1. Biliary obstruction due to tumor invasion; 2. Definite hepatic artery - portal vein fistula; 3. Extensive portal vein cancer embolus with ChildPugh C; 4. Clinically apparent central nervous system metastases or carcinomatous meningitis; 5. Uncontrolled hypertension; 6. History of hemorrhage of digestive tract four weeks ago; 7. Any contraindication of bevacizumab or oxaliplatin; 8. Pregnant or lactating women; 9. History of major operation four weeks ago; 10. Combined with other malignance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to progression;Disease control rate;Tumor response rate;safety (complication and adverse event and laboratory values); | — |
Countries
China
Contacts
Public ContactWeixin Ren
Outcome results
None listed